Roivant Sciences Ltd.
ROIV
NASDAQ·Healthcare·Biotechnology·Mkt cap $24.7B
$34.18
▼ -0.98%
P/E
-131.46
Mkt Cap
$24.7B
52-Wk Range
$12.28–$37.97
52-Week Range
$12.28 - $37.97
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 171.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+19.1% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ROIV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 6, 2026
Reported EPS of -$0.33 vs -$0.30 consensus (-10.1% surprise). Revenue of $1.4M vs $2.1M expected (-31.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-10.1%
Revenue trend · last 1Q
-34%
Q1 26
$1.4M
Margins · last 1Q
Gross
80.3%
Profit
-13164.4%
Wall Street consensus
7 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Aug 25, 2026
vs Industry
How ROIV stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.